OncLive SOSS

Updates on HER2-Directed ADCs Across Solid Tumors - Episode 2

ADCs Targeting HER2+ Breast Cancer

June 25, 2024

Vijayakrishna Gadi, MD, University of Illinois College of Medicine, Susana Campos, MD, MPH, Matthew D. Galsky, MD, Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA, Aparna R. Parikh, MD

Dr Gadi introduces treatment and trial data targeting care for patients diagnosed with HER2+ breast cancer.

EP. 1: Assessing HER2 Status Across Tumor Types

EP. 2: ADCs Targeting HER2+ Breast Cancer

EP. 3: ADCs Targeting HER2+ Gynecologic Cancers

EP. 4: Emerging Data from ASCO 2024 in HER2-low: DESTINY-Breast06

EP. 5: ADCs Targeting GI Cancers

EP. 6: ADCs Targeting HER2+ Lung Cancer

EP. 7: Impact of ADCs on Brain Metastases

EP. 8: ADCs Targeting HER2+ GU Cancers

EP. 9: Overcoming Challenges of Testing for HER2-low Across Solid Tumor Types

EP. 10: The Potential Role for HER2-Targeted ADCs in Earlier Treatment Lines

EP. 11: Managing ILD and Pneumonitis Risk From ADCs

EP. 12: Managing Toxicities in Short- and Long-Term Treatment with ADCs

EP. 13: Managing Hematologic AEs Associated with ADC Treatments

EP. 14: Management of Emetogenicity of Antibody-Drug Conjugates

EP. 15: ADC Sequencing

EP. 16: Emerging ADCs in Development

EP. 17: Insights on T-DXd Approval as Tumor-Agnostic HER2-Directed Therapy

EP. 18: The Future for HER2-Directed ADCs

EP. 19: Key Takeaways and Closing Thoughts on ADCs

Video content above is prompted by the following:

Please briefly review the pivotal data that led to the approval of trastuzumab emtasin (T-DM1) for HER2+ Breast Cancer
- EMILIA and Dieras_Lancet Oncol_2017 Final OS Analysis
- TH3RESA and Krop_Lancet Oncol 2017 Final OS: HER2+ aBC
- KATHERINE and Loibl SABSC Final IDFS and OS Analysis: adjuvant treatment in HER2+ early BC
Please briefly review the data that led to FDA approval for trastuzumab deruxtecan (T-DXd) for HER2+ Breast Cancer, plus other recent updates